Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Keurig Dr Pepper Inc a un objectif de cours consensus de $35.57, basé sur les évaluations des 23 analystes. Le plus élevé est de $42 attribué par HSBC le avril 25, 2025, et le plus bas est de $24 attribué par BNP Paribas le septembre 22, 2025. Les 3 dernières évaluations d'analystes ont été publiées par JP Morgan, B of A Securities et Goldman Sachs le octobre 20, 2025, octobre 8, 2025 et octobre 2, 2025. Avec un objectif de cours moyen de $32.67 entre JP Morgan, B of A Securities et Goldman Sachs, il y a une variation implicite de 12.03% upside pour Keurig Dr Pepper Inc à partir de ces dernières évaluations d'analystes.
1calculé à partir des notes des analystes
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/20/2025 | 23.46% | JP Morgan | $39 → $36 | Maintains | Overweight | |||
10/08/2025 | 13.17% | B of A Securities | $41 → $33 | Maintains | Buy | |||
10/02/2025 | -0.55% | Goldman Sachs | $34 → $29 | Maintains | Neutral | |||
09/25/2025 | 13.17% | Wells Fargo | $40 → $33 | Maintains | Overweight | |||
09/24/2025 | -10.84% | Barclays | $39 → $26 | Downgrade | Overweight → Equal-Weight | |||
09/22/2025 | -17.7% | BNP Paribas | → $24 | Downgrade | Neutral → Underperform | |||
09/17/2025 | 20.03% | Piper Sandler | $40 → $35 | Maintains | Overweight | |||
09/16/2025 | 26.89% | Citigroup | $41 → $37 | Maintains | Buy | |||
08/27/2025 | 20.03% | UBS | $40 → $35 | Maintains | Buy | |||
08/26/2025 | 30.32% | Deutsche Bank | $40 → $38 | Maintains | Buy | |||
08/26/2025 | 2.88% | HSBC | $42 → $30 | Downgrade | Buy → Hold | |||
07/28/2025 | 33.74% | Barclays | $37 → $39 | Maintains | Overweight | |||
07/17/2025 | 30.32% | JP Morgan | $39 → $38 | Maintains | Overweight | |||
07/17/2025 | 37.17% | UBS | $42 → $40 | Maintains | Buy | |||
06/27/2025 | 26.89% | Barclays | $38 → $37 | Maintains | Overweight | |||
04/28/2025 | 30.32% | Barclays | $37 → $38 | Maintains | Overweight | |||
04/25/2025 | 44.03% | HSBC | $36 → $42 | Upgrade | Hold → Buy | |||
04/22/2025 | 44.03% | RBC Capital | $42 → $42 | Reiterates | Outperform → Outperform | |||
04/17/2025 | 44.03% | UBS | $40 → $42 | Maintains | Buy | |||
04/16/2025 | 37.17% | Argus Research | → $40 | Initiates | → Buy | |||
04/09/2025 | 37.17% | Piper Sandler | $35 → $40 | Upgrade | Neutral → Overweight | |||
04/01/2025 | 37.17% | Morgan Stanley | $38 → $40 | Upgrade | Equal-Weight → Overweight | |||
02/27/2025 | 33.74% | Barclays | $36 → $39 | Maintains | Overweight | |||
02/26/2025 | 37.17% | JP Morgan | $37 → $40 | Maintains | Overweight | |||
02/26/2025 | 30.32% | Morgan Stanley | $36 → $38 | Maintains | Equal-Weight | |||
01/17/2025 | 23.46% | Barclays | $39 → $36 | Maintains | Overweight | |||
01/16/2025 | 26.89% | UBS | $42 → $37 | Maintains | Buy | |||
01/08/2025 | 23.46% | TD Cowen | $39 → $36 | Maintains | Hold | |||
01/07/2025 | 37.17% | Wells Fargo | $42 → $40 | Maintains | Overweight | |||
01/07/2025 | 20.03% | Piper Sandler | → $35 | Initiates | → Neutral | |||
12/12/2024 | 33.74% | Deutsche Bank | $37 → $39 | Upgrade | Hold → Buy | |||
10/28/2024 | 33.74% | Barclays | $41 → $39 | Maintains | Overweight | |||
10/25/2024 | 44.03% | UBS | $43 → $42 | Maintains | Buy | |||
10/25/2024 | 37.17% | Citigroup | $43 → $40 | Maintains | Buy | |||
10/25/2024 | 44.03% | RBC Capital | $41 → $42 | Maintains | Outperform | |||
10/25/2024 | 40.6% | Jefferies | $42 → $41 | Maintains | Buy | |||
10/25/2024 | 37.17% | JP Morgan | $41 → $40 | Maintains | Overweight | |||
10/25/2024 | 44.03% | Wells Fargo | $43 → $42 | Maintains | Overweight | |||
10/16/2024 | 40.6% | JP Morgan | $38 → $41 | Maintains | Overweight | |||
10/11/2024 | 40.6% | Barclays | $37 → $41 | Maintains | Overweight | |||
10/07/2024 | 47.46% | UBS | $39 → $43 | Maintains | Buy | |||
09/26/2024 | 37.17% | TD Cowen | $35 → $40 | Maintains | Hold | |||
09/23/2024 | 26.89% | Deutsche Bank | $36 → $37 | Maintains | Hold | |||
09/23/2024 | 47.46% | Citigroup | $36 → $43 | Upgrade | Neutral → Buy | |||
07/26/2024 | 40.6% | RBC Capital | $41 → $41 | Reiterates | Outperform → Outperform | |||
07/19/2024 | 26.89% | Barclays | $38 → $37 | Maintains | Overweight | |||
07/12/2024 | 33.74% | UBS | $40 → $39 | Maintains | Buy | |||
07/10/2024 | 23.46% | JP Morgan | $37 → $36 | Maintains | Overweight | |||
06/24/2024 | 23.46% | Exane BNP Paribas | → $36 | Initiates | → Neutral | |||
06/17/2024 | 16.6% | Truist Securities | $27 → $34 | Upgrade | Sell → Hold | |||
06/10/2024 | 37.17% | UBS | $39 → $40 | Maintains | Buy | |||
06/05/2024 | 40.6% | Wells Fargo | $39 → $41 | Maintains | Overweight | |||
04/29/2024 | 30.32% | Barclays | $36 → $38 | Maintains | Overweight | |||
04/26/2024 | 20.03% | TD Cowen | $32 → $35 | Maintains | Hold | |||
04/12/2024 | 23.46% | Barclays | $32 → $36 | Maintains | Overweight | |||
03/27/2024 | 20.03% | Jefferies | $37 → $35 | Maintains | Buy | |||
03/12/2024 | 9.74% | Barclays | $34 → $32 | Maintains | Overweight | |||
02/26/2024 | 16.6% | Morgan Stanley | $37 → $34 | Maintains | Equal-Weight | |||
02/26/2024 | 20.03% | Wedbush | $37 → $35 | Maintains | Outperform | |||
02/23/2024 | 40.6% | RBC Capital | $42 → $41 | Maintains | Outperform | |||
02/23/2024 | 16.6% | Barclays | $37 → $34 | Maintains | Overweight | |||
01/16/2024 | 26.89% | Barclays | $36 → $37 | Maintains | Overweight | |||
01/03/2024 | 26.89% | Morgan Stanley | → $37 | Downgrade | Overweight → Equal-Weight | |||
12/22/2023 | 26.89% | HSBC | → $37 | Initiates | → Hold | |||
11/13/2023 | 33.74% | Jefferies | → $39 | Initiates | → Buy | |||
10/30/2023 | 23.46% | Barclays | $34 → $36 | Maintains | Overweight | |||
10/27/2023 | 26.89% | Morgan Stanley | $39 → $37 | Maintains | Overweight | |||
10/12/2023 | 16.6% | Barclays | $40 → $34 | Maintains | Overweight | |||
10/12/2023 | 26.89% | Bernstein | $40 → $37 | Maintains | Outperform | |||
10/11/2023 | 13.17% | Citigroup | $37 → $33 | Maintains | Neutral | |||
08/16/2023 | 44.03% | UBS | $37 → $42 | Upgrade | Neutral → Buy | |||
07/28/2023 | 37.17% | Barclays | $37 → $40 | Maintains | Overweight | |||
07/11/2023 | 26.89% | Wedbush | $40 → $37 | Maintains | Outperform | |||
07/11/2023 | 20.03% | Citigroup | $37 → $35 | Maintains | Neutral | |||
07/06/2023 | 26.89% | Morgan Stanley | → $37 | Upgrade | Equal-Weight → Overweight | |||
05/01/2023 | 44.03% | RBC Capital | → $42 | Reiterates | → Outperform | |||
05/01/2023 | 26.89% | Barclays | $42 → $37 | Maintains | Overweight | |||
04/28/2023 | 37.17% | Wedbush | $43 → $40 | Maintains | Outperform | |||
04/28/2023 | 26.89% | Barclays | $42 → $37 | Maintains | Overweight | |||
04/18/2023 | 40.6% | JP Morgan | $40 → $41 | Maintains | Overweight | |||
04/14/2023 | 44.03% | Barclays | $40 → $42 | Maintains | Overweight | |||
03/20/2023 | 23.46% | Deutsche Bank | $38 → $36 | Maintains | Hold | |||
02/27/2023 | 37.17% | Barclays | $45 → $40 | Maintains | Overweight | |||
02/17/2023 | 26.89% | Citigroup | → $37 | Initiates | → Neutral | |||
01/26/2023 | 40.6% | JP Morgan | $40 → $41 | Maintains | Overweight | |||
01/03/2023 | 37.17% | Wells Fargo | $42 → $40 | Maintains | Overweight | |||
12/06/2022 | 33.74% | Deutsche Bank | $38 → $39 | Maintains | Hold | |||
10/31/2022 | 54.32% | Barclays | $41 → $45 | Maintains | Overweight | |||
10/31/2022 | 2.88% | Truist Securities | → $30 | Downgrade | Hold → Sell | |||
10/28/2022 | 44.03% | Wells Fargo | $41 → $42 | Maintains | Overweight |
Le dernier objectif de prix pour Keurig Dr Pepper (NASDAQ:KDP) a été rapporté par JP Morgan le octobre 20, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $36.00 s'attendant à ce que KDP se rise dans les 12 prochains mois (un possible changement de 23.46% upside). 31 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
La dernière note d'analyste pour Keurig Dr Pepper (NASDAQ:KDP) a été fournie par JP Morgan, et Keurig Dr Pepper maintenu leur note overweight.
La dernière amélioration pour Keurig Dr Pepper Inc a eu lieu le avril 25, 2025 lorsque HSBC a augmenté leur objectif de prix à $42. HSBC avait précédemment a hold pour Keurig Dr Pepper Inc.
La dernière réduction pour Keurig Dr Pepper Inc a eu lieu le septembre 24, 2025 lorsque Barclays a changé leur objectif de prix de $39 à $26 pour Keurig Dr Pepper Inc.
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Keurig Dr Pepper, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Keurig Dr Pepper a été déposée le octobre 20, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 20, 2026.
Bien que les évaluations soient subjectives et changeront, la dernière note de Keurig Dr Pepper (KDP) était un maintenu avec un objectif de prix de $39.00 à $36.00. Le prix actuel de Keurig Dr Pepper (KDP) est de $29.16, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.